Next Article in Journal
Maintenance Therapy in Multiple Myeloma
Previous Article in Journal
Histone Deacetylase Inhibitors in Multiple Myeloma
Hematology Reviews (renamed as Hematology Reports here since 2010) is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

The Role of JAK2 Abnormalities in Hematologic Neoplasms

Blood Diseases Center, King Fahad Hofuf Hospital, Hassa P.O. Box 1 31982, Saudi Arabia
Hematol. Rev. 2009, 1(1), e10; (registering DOI)
Received: 3 May 2009 / Revised: 3 June 2009 / Accepted: 24 June 2009 / Published: 9 July 2009


In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.
Keywords: JAK2; myeloproliferative neoplasms; leukaemia JAK2; myeloproliferative neoplasms; leukaemia

Share and Cite

MDPI and ACS Style

Alabdulaali, M.K. The Role of JAK2 Abnormalities in Hematologic Neoplasms. Hematol. Rev. 2009, 1, e10.

AMA Style

Alabdulaali MK. The Role of JAK2 Abnormalities in Hematologic Neoplasms. Hematology Reviews. 2009; 1(1):e10.

Chicago/Turabian Style

Alabdulaali, Mohammed K. 2009. "The Role of JAK2 Abnormalities in Hematologic Neoplasms" Hematology Reviews 1, no. 1: e10.

Article Metrics

Back to TopTop